Needle, the quarterly report for Q1 2023 has not been published,...

First 33 Last

Share
Profile

Follow
Rinnekin

114 Posts.

125

24/04/23

17:06

Post #: 67433755
Share

Originally posted by needle: ↑

There would be 100 new research papers, from around the world..... released each month - whereby the PI3K / mTOR pathway, in the human body, is shown to regulate the progression and regression of cancer and other non- cancer disease.

Obviously I do alot of research on the subject. The volume of information that is released is huge. So much so, that in googling research - I nominate the current month, to isolate or reduce the vast quantity of information.

Why not try google for yourself, to best highlight the untold potential of this drug paxalisib. eg Google search: ......"APRIL 2023 PI3K / mTOR"

You will quickly see dozens of high quality research papers, for this April 23 month alone.

------------------------

So how do we know, such information - pretty much ALL, in fact - relates to Paxalisib.

Well here we are from the company in the March 2023 quarterly report - almost begrudgingly acknowledging that paxalisib works outside the brain. (Information that was first suggested on the chatline 4 years ago) -and now we have this declaration..... "In the context of the previously declared strategy..."

Just missing something in promotion I am afraid - rather missing a hell of a lot, may even be an understatement.

Investers have to cop it - means issue of new shares over many years at a discounted share prices, BUT some sort of opportunity for new investors to enter the stock - at a share price that indeed has an explanation, as to why so cheap.

____________________________________________________

MARCH 23 QUARTERLY REPORT

Positive Preclinical Data for Paxalisib in Melanoma In the context of a previously declared strategy to explore the use of paxalisib in cancers outside the central nervous system, Kazia has entered into a number of research collaborations with leading cancer centres.

Expand

Needle, the quarterly report for Q1 2023 has not been published, yet.
Which quarterly report are you referring to?

KZA Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

HRZ

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Nine's staff strike as Paris Olympic coverage begins

ASX Market Open: ASX200 to rise for Friday session | July 26

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

MIN

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

MND

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

IGO

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

RHK

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit